Results 141 to 150 of about 21,816 (261)

Bionano Interface Optimization for Rational Lateral Flow Assay Development. [PDF]

ACS Nano
Sadler CJ, Miller M, Darmawan KK, Sandler JP, Ng HC, Shamsabadi A, Creamer A, Robinson CV, Yarovsky I, Stevens MM.   +9 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Impact of Variations in Commercial Standard Operating Procedure on Plasma Proteome Recovery. [PDF]

J Proteome Res
Kasai T, Weiss L, Wohlfahrt J, Matamalas JT, Shlayen G, Kirsch ZJ, Aikawa M, Aikawa E, Singh SA.   +8 more
europepmc   +1 more source

Pharmacological activation of NO‐cGMP signalling attenuates metabolic dysfunction‐associated steatohepatitis

British Journal of Pharmacology, EarlyView.
Background and Purpose Metabolic dysfunction‐associated steatohepatitis (MASH) is linked to activation of hepatic stellate cells (HSCs) to α‐smooth muscle actin–positive myofibroblasts that produce collagen and proinflammatory cytokines. Quiescent HSCs express the NO‐cGMP signalling axis.
Krithika Rajeeth, Malte Roessing, Moritz Lehners, Lisa Dietz, Anja Schmitt, Stephan Hailfinger, Andreas Peter, Leticia Quintanilla‐Martinez, Irene Gonzalez‐Menendez, Ingmar Mederacke, German Ott, Peter Sandner, Matthias Schwab, Robert Feil, Susanne Feil   +14 more
wiley   +1 more source

A narrative review of impacts of apolipoproteins on atherosclerotic coronary plaques. [PDF]

NPJ Cardiovasc Health
Fukase T, Dohi T.
europepmc   +1 more source

Effects of Common Food Additives Kappa‐, Iota‐ and Lambda‐Carrageenans on Intestinal Epithelial Cell Activation and Barrier Disruption

Clinical &Experimental Allergy, EarlyView.
Carrageenans, widely used food additives, disrupted intestinal epithelial integrity in a gut‐on‐a‐chip model. All types (κ‐, ɩ‐, λ‐) induced cytotoxicity, inflammation and tight junction (TJ) disruption, triggering TNF‐mediated immune responses. λ‐Carrageenan had the most severe effects, supporting the Epithelial Barrier Theory linking food additives ...
Na Sun, Yagiz Pat, Huseyn Babayev, Sena Ardicli, Ismail Ogulur, Xianting Bu, Manru Li, Shuqi Jia, Beate Rückert, Raja Dhir, Kari C. Nadeau, Mubeccel Akdis, Cezmi A. Akdis, Duygu Yazici   +13 more
wiley   +1 more source

Accounting for Differences in Plasma Protein Binding between Fish and Humans for Supporting Environmental Risk Assessment of Pharmaceuticals Using the Fish Plasma Model. [PDF]

Environ Sci Technol
Brown AR, Trznadel M, Pedersen S, Nimrod Perkins A, Lee M, Mohutsky M, Bell A, Pihlaja TL, Sikanen T, Weil M, Coors A, Wilson RW, Tyler CR.   +12 more
europepmc   +1 more source

Unveiling Gut Homeostasis Disruption in Sepsis: Towards an Integrated Mechanistic and Translational Roadmap

Cell Proliferation, EarlyView.
Elucidating the contribution of gut‐organ axes will provide new insights for developing combined therapeutic strategies against sepsis‐associated multiple organ dysfunction. ABSTRACT Sepsis, a life‐threatening clinical syndrome precipitated by a maladaptive host response to infection, is associated with substantial morbidity and high mortality rates ...
Yichen Bao, Lin Qi, Guijun Zou, Xingpeng Yang, Yizhao Ma, Zhifu Li, Xiaohui Du, Pengyue Zhao   +7 more
wiley   +1 more source

Apolipoproteins in Chronic Kidney Disease and Kidney Transplant: A Long Unfinished Story. [PDF]

Int J Mol Sci
Secondulfo C, Izzo C, Vecchione N, Minelli G, Russo D, Russo D, Barra R, Molinaro G, Apicella L, Iacuzzo C, Pisani A, Hamzeh S, Amicone M, Cirillo M, Bilancio G.   +14 more
europepmc   +1 more source

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source